Iridian Asset Management’s Myriad Genetics MYGN Stock Holding History

Iridian Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,215,862	Closed	-$98.4M	–	82
2016 Q2	$98.4M	Sell	3,215,862 -1,292,487	-29%	-$44.9M	0.91%	42
2016 Q1	$169M	Buy	4,508,349 +617,277	+16%	+$23.3M	1.43%	29
2015 Q4	$168M	Sell	3,891,072 -1,389,236	-26%	-$58.7M	1.38%	31
2015 Q3	$198M	Sell	5,280,308 -522,777	-9%	-$18.6M	1.67%	26
2015 Q2	$197M	Buy	5,803,085 +391,520	+7%	+$13.3M	1.55%	32
2015 Q1	$192M	Buy	5,411,565 +1,432,661	+36%	+$51.3M	1.61%	30
2014 Q4	$136M	Buy	3,978,904 +593,990	+18%	+$21.1M	1.26%	33
2014 Q3	$131M	Buy	3,384,914 +688,698	+26%	+$25.7M	1.35%	33
2014 Q2	$105M	Buy	2,696,216 +128,290	+5%	+$4.77M	1.08%	36
2014 Q1	$87.8M	Buy	+2,567,926	New	+$79.6M	1%	37

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Iridian Asset Management's MYGN Position: Q3 2016 in Review

Iridian Asset Management sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 3,215,862 shares — an estimated $98.4M sold.

Iridian Asset Management first reported a position in MYGN in Q1 2014 and held it in 10 quarters. The position peaked at $198M in Q3 2015. 224 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

Iridian Asset Management reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
Iridian Asset Management sold 3,215,862 Myriad Genetics shares in Q3 2016, an estimated $98.4M.
Iridian Asset Management first reported a position in Myriad Genetics in Q1 2014 and held it in 10 quarters.
Iridian Asset Management's Myriad Genetics position peaked at $198M in Q3 2015.
224 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Iridian Asset Management's 13F filing for Q3 2016, filed 9 Nov 2016.